Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Adenocarcinoma Of The Gastroesophageal Junction-Pipeline Review, H1 2015

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Adenocarcinoma Of The Gastroesophageal Junction-Pipeline Review, H1 2015', provides an overview of the Adenocarcinoma Of The Gastroesophageal Junction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Adenocarcinoma Of The Gastroesophageal Junction

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Adenocarcinoma Of The Gastroesophageal Junction and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Adenocarcinoma Of The Gastroesophageal Junction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Adenocarcinoma Of The Gastroesophageal Junction pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Adenocarcinoma Of The Gastroesophageal Junction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Adenocarcinoma Of The Gastroesophageal Junction Overview 9

Therapeutics Development 10

Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction-Overview 10

Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction-Comparative Analysis 11

Adenocarcinoma Of The Gastroesophageal Junction-Therapeutics under Development by Companies 12

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Adenocarcinoma Of The Gastroesophageal Junction-Products under Development by Companies 17

Adenocarcinoma Of The Gastroesophageal Junction-Companies Involved in Therapeutics Development 19

AB Science 19

Amgen Inc. 20

Apceth GmbH & Co. KG 21

ArQule, Inc. 22

AstraZeneca PLC 23

Boehringer Ingelheim GmbH 24

Boston Biomedical, Inc. 25

Bristol-Myers Squibb Company 26

Cerulean Pharma, Inc. 27

Eli Lilly and Company 28

Epirus Biopharmaceuticals, Inc. 29

F. Hoffmann-La Roche Ltd. 30

Ganymed Pharmaceuticals AG 31

Genentech, Inc. 32

Gilead Sciences, Inc. 33

Mebiopharm Co., Ltd. 34

MedImmune, LLC 35

Merck & Co., Inc. 36

Merck KGaA 37

Millennium Pharmaceuticals, Inc. 38

Novartis AG 39

Panacea Biotec Limited 40

Sanofi 41

Adenocarcinoma Of The Gastroesophageal Junction-Therapeutics Assessment 42

Assessment by Monotherapy Products 42

Assessment by Combination Products 43

Assessment by Target 44

Assessment by Mechanism of Action 47

Assessment by Route of Administration 49

Assessment by Molecule Type 51

Drug Profiles 53

Agenmestencel-T-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

alpelisib-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

AMG-337-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

avelumab-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

AZD-4547-Drug Profile 59

AZD-4547-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

BI-853520-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

BMS-833923-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

cabazitaxel-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

catumaxomab-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

CRLX-101-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

durvalumab + tremelimumab-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

emibetuzumab-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

erismodegib-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

GS-5745-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

IMAB-362-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

indusatumab vedotin-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

ipatasertib-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

masitinib-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

MBP-426-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

napabucasin-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

panitumumab-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

pembrolizumab-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

ramucirumab-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

solitomab-Drug Profile 106

Product Description 106

Mechanism of Action 106

R&D Progress 106

tivantinib-Drug Profile 107

Product Description 107

Mechanism of Action 107

R&D Progress 107

trastuzumab biosimilar-Drug Profile 110

Product Description 110

Mechanism of Action 110

R&D Progress 110

trastuzumab biosimilar-Drug Profile 111

Product Description 111

Mechanism of Action 111

R&D Progress 111

trastuzumab biosimilar-Drug Profile 112

Product Description 112

Mechanism of Action 112

R&D Progress 112

trastuzumab emtansine-Drug Profile 113

Product Description 113

Mechanism of Action 113

R&D Progress 113

Adenocarcinoma Of The Gastroesophageal Junction-Recent Pipeline Updates 117

Adenocarcinoma Of The Gastroesophageal Junction-Dormant Projects 162

Adenocarcinoma Of The Gastroesophageal Junction-Discontinued Products 163

Adenocarcinoma Of The Gastroesophageal Junction-Product Development Milestones 164

Featured News & Press Releases 164

May 18, 2015: AB Science announces that three clinical abstracts will be presented at the 2015 ASCO annual meeting 164

Jul 22, 2014: Ganymed Completes Recruitment for Randomized Phase 2 FAST Trial of IMAB362 for Gastroesophageal Cancer 166

Jan 23, 2014: apceth's Ground-Breaking First-In-Man, First-In-Class Clinical Trial in Oncology with Genetically Modified Mesenchymal Stromal Cells Is Now Enrolling 166

Appendix 168

Methodology 168

Coverage 168

Secondary Research 168

Primary Research 168

Expert Panel Validation 168

Contact Us 168

Disclaimer 169

List of Tables

Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H1 2015 10

Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Development by Companies, H1 2015 (Contd..1) 13

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Development by Companies, H1 2015 (Contd..1) 18

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by AB Science, H1 2015 19

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Amgen Inc., H1 2015 20

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Apceth GmbH & Co. KG, H1 2015 21

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by ArQule, Inc., H1 2015 22

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by AstraZeneca PLC, H1 2015 23

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Boehringer Ingelheim GmbH, H1 2015 24

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Boston Biomedical, Inc., H1 2015 25

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Bristol-Myers Squibb Company, H1 2015 26

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Cerulean Pharma, Inc., H1 2015 27

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Eli Lilly and Company, H1 2015 28

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 29

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 30

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Ganymed Pharmaceuticals AG, H1 2015 31

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Genentech, Inc., H1 2015 32

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Gilead Sciences, Inc., H1 2015 33

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Mebiopharm Co., Ltd., H1 2015 34

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by MedImmune, LLC, H1 2015 35

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Merck & Co., Inc., H1 2015 36

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Merck KGaA, H1 2015 37

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 38

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Novartis AG, H1 2015 39

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Panacea Biotec Limited, H1 2015 40

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Sanofi, H1 2015 41

Assessment by Monotherapy Products, H1 2015 42

Assessment by Combination Products, H1 2015 43

Number of Products by Stage and Target, H1 2015 45

Number of Products by Stage and Mechanism of Action, H1 2015 48

Number of Products by Stage and Route of Administration, H1 2015 50

Number of Products by Stage and Molecule Type, H1 2015 52

Adenocarcinoma Of The Gastroesophageal Junction Therapeutics-Recent Pipeline Updates, H1 2015 117

Adenocarcinoma Of The Gastroesophageal Junction-Dormant Projects, H1 2015 162

Adenocarcinoma Of The Gastroesophageal Junction-Discontinued Products, H1 2015 163

List of Figures

Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H1 2015 10

Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 15

Assessment by Monotherapy Products, H1 2015 42

Number of Products by Top 10 Targets, H1 2015 44

Number of Products by Stage and Top 10 Targets, H1 2015 45

Number of Products by Top 10 Mechanism of Actions, H1 2015 47

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 47

Number of Products by Top 10 Routes of Administration, H1 2015 49

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 50

Number of Products by Top 10 Molecule Types, H1 2015 51

Number of Products by Stage and Top 10 Molecule Types, H1 2015 52

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science

Amgen Inc.

Apceth GmbH & Co. KG

ArQule, Inc.

AstraZeneca PLC

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Cerulean Pharma, Inc.

Eli Lilly and Company

Epirus Biopharmaceuticals, Inc.

F. Hoffmann-La Roche Ltd.

Ganymed Pharmaceuticals AG

Genentech, Inc.

Gilead Sciences, Inc.

Mebiopharm Co., Ltd.

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

Millennium Pharmaceuticals, Inc.

Novartis AG

Panacea Biotec Limited

Sanofi

Adenocarcinoma Of The Gastroesophageal Junction Therapeutic Products under Development, Key Players in Adenocarcinoma Of The Gastroesophageal Junction Therapeutics, Adenocarcinoma Of The Gastroesophageal Junction Pipeline Overview, Adenocarcinoma Of The Gastroesophageal Junction Pipeline, Adenocarcinoma Of The Gastroesophageal Junction Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com